MGNX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
MacroGenics Inc (MGNX) is a good buy for a beginner investor with a long-term horizon and $50,000-$100,000 available for investment. The stock has strong positive catalysts, including bullish analyst upgrades, resumed clinical trials, and a significant revenue growth trend. Despite some financial challenges, the current price of $3.41 offers an attractive entry point given the long-term potential and positive sentiment.
The technical indicators show mixed signals. While the MACD is negatively expanding and below zero, the RSI is neutral at 55.733. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading near its pivot level of 3.369, with resistance levels at 3.77 and 4.018. This suggests some upside potential in the near term.
FDA lifted the partial clinical hold on Lorigerlimab Phase 2 trial, resuming patient enrollment.
B. Riley upgraded the stock to 'Buy' with a $9 price target, citing strong potential in the Antibody-Drug Conjugate market.
Revenue increased by 113.03% YoY in Q4
Retail sentiment shifted from bearish to bullish, reflecting increased investor confidence.
Net income dropped by -8.21% YoY, and EPS declined by -12.00% YoY in Q4
MACD is negatively expanding, indicating some short-term bearish momentum.
In Q4 2025, revenue surged by 113.03% YoY to $41.23M, showing strong growth. However, net income decreased by -8.21% YoY to -$14.16M, and EPS dropped by -12.00% YoY to -0.22. Gross margin improved to 75.47%, up 5.36% YoY, indicating better operational efficiency.
Analysts are bullish on MGNX. B. Riley upgraded the stock to 'Buy' with a $9 price target, citing its unique position in the next-gen Antibody-Drug Conjugate market. Barclays also raised its price target to $4 from $3, maintaining an Overweight rating.
